Page History

Overview

The Medicinal |Product Form "containing" (MPF-containing) concept is containing x in y dose form (medicinal product form)| concept is an abstract representation of active ingredient(s) and dose form intended site for a medicinal product.  It means that the medicinal product must contain the The medicinal product must contain the active ingredient(s) specified in the FSN but may FSN but may also contain a modification of the active ingredient(s) specified in the FSN or may contain additional active ingredient(s) as well.Example:

For example,

• • Product containing axitinib in oral dose form (medicinal product form)
  • Product containing abacavir and lamivudine in oral dose form (medicinal product form)

Modeling

...

MPF-containing concepts shall be modeled using the proximal primitive modeling pattern.

concept

Stated parent		763158003 |Medicinal product (product)
Semantic tag	(medicinal product form)
Definition status	900000000000073002 |Sufficiently defined by necessary conditions definition status (core metadata concept)|Defined
Attribute: Has active ingredient	Range: 105590001 <105590001 |Substance (substance) - descendants only|, excluding concepts representing structural groupers, dispositions, or roles Cardinality: 1..* There is no technical limit on the number of Has active ingredient attributes that may be added to a concept; a practical limit may be imposed at a later date. For content in the International Release, this attribute value should represent the base ingredient, not a modification, unless explicitly identified as an exception. Exceptions: Chemical element with multiple modification (e.g. 422232005 |Calcium lactate gluconate (substance)|) Chloral hydrate (e.g. 386735001 |Product containing chloral hydrate in oral dose form (medicinal product form)|) Liposome or lipid complex substances(e.g. 426490000 |Vincristine liposome (substance)|, 425953004 |Amphotericin B lipid complex (substance)|, 768664009 |Amphotericin B phospholipid complex (substance)|, 427544000 |Amphotericin B cholesteryl sulfate complex (substance)|) Pegylated substance (e.g . 385544005 |Pegfilgrastim (substance)|, 770965008 |Pegvaliase (substance)|) Radiopharmaceutical (e.g. 783866002 |Product containing cyanocobalamin (58-Co) in oral dose form (medicinal product form)|, 783856005 |Product containing sodium iodide (131-I) in parenteral dose form (medicinal product form)|) Silver sulfadiazine (e.g. 771756000 |Product containing silver sulfadiazine in cutaneous dose form (medicinal product form)|) Benzylpenicillin (e.g. 713760005 |Product containing benzathine benzylpenicillin in parenteral dose form (medicinal product form)|)
Attribute: Has manufactured dose form	Range: 736542009 |Pharmaceutical dose form (dose form) - descendants that are groupers representing intended site only (e.g. 385268001 |Oral dose form (dose form)|, 385287007 |Parenteral dose form (dose form)|) Cardinality: 1..1 Exceptions:  385217004 |Conventional release gas for inhalation (dose form)| may be used as manufactured dose form for Medicinal product form concepts. 785898006 |Conventional release solution for irrigation (dose form)| does not have 736474004 |Has dose form intended site (attribute)| but can be used as a target for manufactured dose form for Medicinal product form concepts.

Naming

...

Use the following pattern for the FSN

...

and PT.  Align naming and case sensitivity with the FSN for the concepts that are selected as the attribute value

...

.

For multiple ingredient drug products,

...

active ingredients must be in alphabetical order and separated by the word “and”.

FSN

Product containing <Active ingredient FSN> in <Manufactured dose form FSN> (medicinal product form) Product containing <Active ingredient FSN> and <Active ingredient FSN> in <Manufactured dose form FSN> (medicinal product form) Product containing <Active ingredient FSN> and <Active ingredient FSN> and <Active ingredient FSN> in <Manufactured dose form FSN> (medicinal product form) For example, Product containing axitinib in oral dose form (medicinal product form) Product containing abacavir and lamivudine in oral dose form (medicinal product form) Product containing abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) Creation of MPF-containing concepts for all possible combinations of active ingredients contained in multiple ingredient products is not recommended at this time (no specific use case has been identified). For example, a product containing three active ingredients would only require creation of one MPF-containing concept. If any of the active ingredients is available as a single ingredient product, or as part of another multiple ingredient concept, then appropriate concepts would be created for those products.

For example,

• • • Product containing axitinib in oral dose form (medicinal product form)
    • Product containing abacavir and lamivudine in oral dose form (medicinal product form)
    • Product containing abacavir and lamivudine and zidovudine in oral dose form (medicinal product form)

Preferred Term

Use the following pattern for the PT; align naming and case sensitivity with the PT for the concept that is selected as the attribute value. For multiple ingredient drug products, the active ingredients must be in alphabetical order and separated by the word “and”.

<Active ingredient PT>-containing product in <Manufactured dose form PT> <Active ingredient PT>- and <Active ingredient PT>-containing product in <Manufactured dose form PT> <Active ingredient PT>- and <Active ingredient PT>- and <Active ingredient PT>-containing product in <Manufactured dose form PT> For example, Axitinib-containing product in oral dose form Abacavir- and lamivudine-containing product in oral dose form Abacavir- and lamivudine- and zidovudine-containing product in oral dose form

Synonym

Synonyms matching the FSN are not required.

Exemplars

The following illustrates the stated view for 773391004 |Product containing axitinib in oral dose form (medicinal product form)|

...